DNMT1 and primary cutaneous T-cell non-Hodgkin lymphoma: Small molecules that inhibit the action of certain epigenetic proteins in cancer have met success to cure cancer, for example, recently FDA approved the use of vorinostat and romidepsin (HDAC inhibitors); azacitidine and decitabine (DNMT inhibitors) for treatment of cutaneous T cell lymphoma and myelodysplastic syndrome7, 8, 9.